365 related articles for article (PubMed ID: 16230074)
21. [Five years trial of entecavir for chronic hepatitis B patients failed with lamivudine therapy in the Chongqing area].
LI H; WANG ZY; ZHANG DZ; SHI XF; ZHOU Z; REN H
Zhonghua Gan Zang Bing Za Zhi; 2009 May; 17(5):338-41. PubMed ID: 19497197
[TBL] [Abstract][Full Text] [Related]
22. Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety.
Yuen MF; Seto WK; Fung J; Wong DK; Yuen JC; Lai CL
Am J Gastroenterol; 2011 Jul; 106(7):1264-71. PubMed ID: 21364549
[TBL] [Abstract][Full Text] [Related]
23. Entecavir for the treatment of chronic hepatitis B virus infection.
Matthews SJ
Clin Ther; 2006 Feb; 28(2):184-203. PubMed ID: 16678641
[TBL] [Abstract][Full Text] [Related]
24. Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy.
Reijnders JG; Pas SD; Schutten M; de Man RA; Janssen HL
J Hepatol; 2009 Apr; 50(4):674-83. PubMed ID: 19231002
[TBL] [Abstract][Full Text] [Related]
25. Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy.
Yuen MF; Fung J; Seto WK; Wong DK; Yuen JC; Lai CL
Antivir Ther; 2009; 14(5):679-85. PubMed ID: 19704171
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis.
Schiff E; Simsek H; Lee WM; Chao YC; Sette H; Janssen HL; Han SH; Goodman Z; Yang J; Brett-Smith H; Tamez R
Am J Gastroenterol; 2008 Nov; 103(11):2776-83. PubMed ID: 18721244
[TBL] [Abstract][Full Text] [Related]
27. Entecavir resistance is rare in nucleoside naïve patients with hepatitis B.
Colonno RJ; Rose R; Baldick CJ; Levine S; Pokornowski K; Yu CF; Walsh A; Fang J; Hsu M; Mazzucco C; Eggers B; Zhang S; Plym M; Klesczewski K; Tenney DJ
Hepatology; 2006 Dec; 44(6):1656-65. PubMed ID: 17133475
[TBL] [Abstract][Full Text] [Related]
28. A randomized double-blind placebo-controlled study of lamivudine in the treatment of patients with chronic hepatitis B virus infection.
Yao G; Wang B; Cui Z; Yao J; Zeng M
Chin Med J (Engl); 1999 May; 112(5):387-91. PubMed ID: 11593504
[TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection.
de Man RA; Wolters LM; Nevens F; Chua D; Sherman M; Lai CL; Gadano A; Lee Y; Mazzotta F; Thomas N; DeHertogh D
Hepatology; 2001 Sep; 34(3):578-82. PubMed ID: 11526545
[TBL] [Abstract][Full Text] [Related]
30. Clinical outcomes of chronic hepatitis B patients with persistently detectable serum hepatitis B virus DNA during lamivudine therapy.
Kim JH; Yu SK; Seo YS; Yim HJ; Yeon JE; Park JJ; Kim JS; Bak YT; Lee CH; Byun KS
J Gastroenterol Hepatol; 2007 Aug; 22(8):1220-5. PubMed ID: 17532786
[TBL] [Abstract][Full Text] [Related]
31. Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C.
Pan XP; Li LJ; Du WB; Li MW; Cao HC; Sheng JF
J Viral Hepat; 2007 Nov; 14(11):767-74. PubMed ID: 17927612
[TBL] [Abstract][Full Text] [Related]
32. A 7-year study of lamivudine therapy for hepatitis B virus e antigen-positive chronic hepatitis B patients in China.
Yao GB; Zhu M; Cui ZY; Wang BE; Yao JL; Zeng MD
J Dig Dis; 2009 May; 10(2):131-7. PubMed ID: 19426396
[TBL] [Abstract][Full Text] [Related]
33. Entecavir: a new nucleoside analog for the treatment of chronic hepatitis B infection.
Sims KA; Woodland AM
Pharmacotherapy; 2006 Dec; 26(12):1745-57. PubMed ID: 17125436
[TBL] [Abstract][Full Text] [Related]
34. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.
Lai CL; Chien RN; Leung NW; Chang TT; Guan R; Tai DI; Ng KY; Wu PC; Dent JC; Barber J; Stephenson SL; Gray DF
N Engl J Med; 1998 Jul; 339(2):61-8. PubMed ID: 9654535
[TBL] [Abstract][Full Text] [Related]
35. Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment.
Fung J; Lai CL; Young J; Wong DK; Yuen J; Seto WK; Yuen MF
Am J Gastroenterol; 2011 Oct; 106(10):1766-73. PubMed ID: 21826112
[TBL] [Abstract][Full Text] [Related]
36. [Efficacy and predictors of the virologic response to entecavir therapy in nucleoside-naive patients with chronic hepatitis B].
Myung HJ; Jeong SH; Kim JW; Kim HS; Jang JH; Lee DH; Kim N; Hwang JH; Park YS; Lee SH
Korean J Hepatol; 2010 Mar; 16(1):57-65. PubMed ID: 20375643
[TBL] [Abstract][Full Text] [Related]
37. Telbivudine versus lamivudine in patients with chronic hepatitis B.
Lai CL; Gane E; Liaw YF; Hsu CW; Thongsawat S; Wang Y; Chen Y; Heathcote EJ; Rasenack J; Bzowej N; Naoumov NV; Di Bisceglie AM; Zeuzem S; Moon YM; Goodman Z; Chao G; Constance BF; Brown NA;
N Engl J Med; 2007 Dec; 357(25):2576-88. PubMed ID: 18094378
[TBL] [Abstract][Full Text] [Related]
38. [Chronic hepatitis B treated with domestic manufactured lamivudine in 2200 patients: a phase IV study].
Yao GB; Cui ZY; Yao JL; Zhang DF; Ji NX; Huang Y
Zhonghua Gan Zang Bing Za Zhi; 2003 Feb; 11(2):103-8. PubMed ID: 12648409
[TBL] [Abstract][Full Text] [Related]
39. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial.
Hou J; Yin YK; Xu D; Tan D; Niu J; Zhou X; Wang Y; Zhu L; He Y; Ren H; Wan M; Chen C; Wu S; Chen Y; Xu J; Wang Q; Wei L; Chao G; Constance BF; Harb G; Brown NA; Jia J
Hepatology; 2008 Feb; 47(2):447-54. PubMed ID: 18080339
[TBL] [Abstract][Full Text] [Related]
40. [Clinical efficacy of entecavir therapy and factors associated with treatment response in naive chronic hepatitis B patients].
Lee MH; Lim SG; Jeon SJ; Kang CJ; Cho YJ; Kim SS; Lee D; Cheong JY; Cho SW
Korean J Hepatol; 2009 Dec; 15(4):446-53. PubMed ID: 20037263
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
